A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Latest Information Update: 14 Mar 2024
At a glance
- Drugs JS 105 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Risen Pharma
Most Recent Events
- 05 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Jan 2024 Status changed from planning to not yet recruiting.
- 18 Apr 2023 New trial record